Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma

Clinical Endocrinology

Volumn 75, Issue 5, 2011, Pages 585-591

  Kroiss, Matthias ^a   Quinkler, Marcus ^b   Lutz, Werner K ^c   Allolio, Bruno ^a   Fassnacht, Martin ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; CERIVASTATIN; CYTOCHROME P450 3A4; DEXAMETHASONE; DIAZEPAM; ESTRADIOL; ESZOPICLONE; GLUCOCORTICOID; GRANISETRON; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MIDAZOLAM; MITOTANE; ONDANSETRON; OPIATE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; OXYCODONE; PRAVASTATIN; PREDNISOLONE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN 3 ANTAGONIST; SIMVASTATIN; SUNITINIB; TESTOSTERONE; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; LIVER METABOLISM; PRIORITY JOURNAL; REVIEW; STEROID METABOLISM;

ADRENOCORTICAL CARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; INDOLES; MITOTANE; PYRROLES;

EID: 80054769146     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04214.x     Document Type: Review

References (77)

1. Fassnacht, M., Libé, R., Kroiss, M., et al. (2011) Adrenocortical carcinoma: a clinician's update. Nature Reviews Endocrinology, 7, 323-335.
2. Bergenstal, D., Lipsett, M., Moy, R., et al. (1959) Regression of adrenal cancer and suppression of adrenal function in men by o,p-DDD. Transactions of theAssociation of American Physicians, 72, 341.
3. Terzolo, M., Angeli, A., Fassnacht, M., et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine, 356, 2372-2380. (Pubitemid 46883771)
4. Hahner, S., &, Fassnacht, M., (2005) Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs, 6, 386.
5. van Erp, N.P., Guchelaar, H.J., Ploeger, B.A., et al. (2011) Mitotane has a strong and a durable inducing effect on CYP3A4 activity. European Journal of Endocrinology, 164, 621-626.
6. van Erp, N.P., Baker, S.D., Zandvliet, A.S., et al. (2011) Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemotherapy and Pharmacology, 67, 695-703.
7. Hart, L.G., &, Fouts, J.R., (1963) Effects of acute and chronic DDT administration on hepatic microsomal drug metabolism in the rat. Proceedings of the Society for Experimental Biology and Medicine, 114, 388-392.
8. Welch, R.M., Levin, W., &, Conney, A.H., (1967) Insecticide inhibition and stimulation of steroid hydroxylases in rat liver. Journal of Pharmacology and Experimental Therapeutics, 155, 167-173.
9. Street, J.C., (1969) VI. Biochemical and pathological effects. Organochlorine insecticides and the stimulation of liver microsome enzymes. Annals of the New York Academy of Sciences, 160, 274-290.
10. Medina-Diaz, I.M., &, Elizondo, G., (2005) Transcriptional induction of CYP3A4 by o,p'-DDT in HepG2 cells. Toxicology Letters, 157, 41-47. (Pubitemid 40410611)
11. Medina-Diaz, I.M., Arteaga-Illan, G., de Leon, M.B., et al. (2007) Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metabolism and Disposition, 35, 95-102. (Pubitemid 46036481)
12. Wyde, M.E., Bartolucci, E., Ueda, A., et al. (2003) The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Molecular Pharmacology, 64, 474-481. (Pubitemid 36910012)
13. Fukushima, D.K., Bradlow, H.L., &, Hellman, L., (1971) Effects of o,p'-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man. Journal of Clinical Endocrinology and Metabolism, 32, 192-200.
14. Hellman, L., Weitzman, E.D., Roffwarg, H., et al. (1970) Effect of o,p'-DDD on cortisol secretory pattern in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 31, 227-230.
15. Bledsoe, T., Island, D.P., Ney, R.L., et al. (1964) An effect of o,p'-DDD on the extra-adrenal metabolism of cortisol in man. Journal of Clinical Endocrinology and Metabolism, 24, 1303-1311.
16. Southren, A.L., Tochimoto, S., Isurugi, K., et al. (1966) The effect of 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) on the metabolism of infused cortisol-7-3H. Steroids, 7, 11-29.
17. Werk E.E., Jr, Macgee, J., &, Sholiton, L.J., (1964) Effect of diphenylhydantoin on cortisol metabolism in man. Journal of Clinical Investigation, 43, 1824-1835.
18. Thrasher, K., Werk E.E., Jr, Choi, Y., et al. (1969) The measurement, excretion, and source of urinary 6-hydroxycortisol in humans. Steroids, 14, 455-468.
19. Choi, Y., Thrasher, K., Werk E.E., Jr, et al. (1971) Effect of diphenylhydantoin on cortisol kinetics in humans. Journal of Pharmacology and Experimental Therapeutics, 176, 27-34.
20. Conney, A.H., (1967) Pharmacological implications of microsomal enzyme induction. Pharmacological Reviews, 19, 317-366.
21. Bienvenu, T., Rey, E., Pons, G., et al. (1991) A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. International Journal of Clinical Pharmacology, Therapy and Toxicology, 29, 441-445.
22. Lutz, U., Bittner, N., Ufer, M., et al. (2010) Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 878, 97-101.
23. Petersen, M.S., Halling, J., Damkier, P., et al. (2007) Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicology and Applied Pharmacology, 224, 202-206. (Pubitemid 47494519)
24. van Seters, A.P., &, Moolenaar, A.J., (1991) Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinologica, 124, 526-533.
25. Alexandraki, K.I., Kaltsas, G.A., le Roux, C.W., et al. (2010) Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical Endocrinology, 72, 305-311.
26. Robinson, B.G., Hales, I.B., Henniker, A.J., et al. (1987) The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clinical Endocrinology, 27, 437-444. (Pubitemid 17148599)
27. Lin, J.H., &, Lu, A.Y., (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361-390. (Pubitemid 28520008)
28. Dresser, G.K., Spence, J.D., &, Bailey, D.G., (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics, 38, 41-57. (Pubitemid 30055093)
29. Anzenbacher, P., &, Anzenbacherova, E., (2001) Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Life Sciences, 58, 737-747. (Pubitemid 32553031)
30. Shaw, P.N., Houston, J.B., Rowland, M., et al. (1985) Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. British Journal of Clinical Pharmacology, 20, 611-618. (Pubitemid 16184101)
31. Villikka, K., Kivisto, K.T., &, Neuvonen, P.J., (1998) The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacology and Toxicology, 83, 135-138. (Pubitemid 28432381)
32. Lecamwasam, D.S., Franklin, C., &, Turner, P., (1975) Effect of phenobarbitone on hepatic drug-metabolizing enzymes and urinary D-glucaric acid excretion in man. British Journal of Clinical Pharmacology, 2, 257-262.
33. Sahi, J., Black, C.B., Hamilton, G.A., et al. (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition, 31, 439-446. (Pubitemid 36378521)
34. Combalbert, J., Fabre, I., Fabre, G., et al. (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metabolism and Disposition, 17, 197-207. (Pubitemid 19083606)
35. Capewell, S., Freestone, S., Critchley, J.A., et al. (1988) Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet, 332, 480-482.
36. Michelucci, R., Cipolla, G., Passarelli, D., et al. (1996) Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia, 37, 1107-1110. (Pubitemid 26391243)
37. Wang, R.W., Newton, D.J., Scheri, T.D., et al. (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metabolism and Disposition, 25, 502-507. (Pubitemid 27209375)
38. Beaird, S.L., (2000) HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. Journal of the American Pharmaceutical Association (Washington, DC), 40, 637-644.
39. Neuvonen, P.J., Kantola, T., &, Kivisto, K.T., (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clinical Pharmacology and Therapeutics, 63, 332-341. (Pubitemid 28182231)
40. Okudaira, T., Kotegawa, T., Imai, H., et al. (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. Journal of Clinical Pharmacology, 47, 871-876.
41. Baciewicz, A.M., &, Baciewicz F.A., Jr, (1993) Ketoconazole and fluconazole drug interactions. Archives of Internal Medicine, 153, 1970-1976. (Pubitemid 23263558)
42. Venkatakrishnan, K., von Moltke, L.L., &, Greenblatt, D.J., (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clinical Pharmacokinetics, 38, 111-180. (Pubitemid 30122116)
43. Tucker, R.M., Denning, D.W., Hanson, L.H., et al. (1992) Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clinical Infectious Diseases, 14, 165-174.
44. Abadie-Kemmerly, S., Pankey, G.A., &, Dalovisio, J.R., (1988) Failure of ketoconazole treatment of Blastomyces dermatitidis due to interaction of isoniazid and rifampin. Annals of Internal Medicine, 109, 844-845. (Pubitemid 19046057)
45. Ferguson, R.M., Sutherland, D.E., Simmons, R.L., et al. (1982) Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet, 2, 882-883. (Pubitemid 12018568)
46. Schroeder, T.J., Melvin, D.B., Clardy, C.W., et al. (1987) Use of cyclosporine and ketoconazole without nephrotoxicity in two heart transplant recipients. Journal of Heart Transplantation, 6, 84-89. (Pubitemid 17110728)
47. Gomez, D.Y., Wacher, V.J., Tomlanovich, S.J., et al. (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics, 58, 15-19.
48. Keogh, A., Spratt, P., McCosker, C., et al. (1995) Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. New England Journal of Medicine, 333, 628-633.
49. Igaz, P., Tombol, Z., Szabo, P.M., et al. (2008) Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Current Medicinal Chemistry, 15, 2734-2747.
50. Wright, M.C., Paine, A.J., Skett, P., et al. (1994) Induction of rat hepatic glucocorticoid-inducible cytochrome P450 3A by metyrapone. Journal of Steroid Biochemistry and Molecular Biology, 48, 271-276. (Pubitemid 24131825)
51. Harvey, J.L., Paine, A.J., Maurel, P., et al. (2000) Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4. Drug Metabolism and Disposition, 28, 96-101. (Pubitemid 30027518)
52. Williams, P.A., Cosme, J., Vinkovic, D.M., et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 305, 683-686. (Pubitemid 39006760)
53. Cuddy, P.G., &, Loftus, L.S., (1986) Influence of mitotane on the hypoprothrombinemic effect of warfarin. Southern Medical Journal, 79, 387-388.
54. Rettie, A.E., Korzekwa, K.R., Kunze, K.L., et al. (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5, 54-59.
55. Flockhart, D., (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine, http://medicine.iupui.edu/ clinpharm/ddis/table.aspx. Accessed 01/08/2011.
56. Berruti, A., Terzolo, M., Sperone, P., et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer, 12, 657-666. (Pubitemid 41482999)
57. Berruti, A., Ferrero, A., Sperone, P., et al. (2008) Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 13, 497-509.
58. Khan, T.S., Imam, H., Juhlin, C., et al. (2000) Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology, 11, 1281-1287.
59. Kawashiro, T., Yamashita, K., Zhao, X.J., et al. (1998) A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 286, 1294-1300. (Pubitemid 29135542)
60. Zhuo, X., Zheng, N., Felix, C.A., et al. (2004) Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metabolism and Disposition, 32, 993-1000. (Pubitemid 39096060)
61. Bates, S.E., Shieh, C.Y., Mickley, L.A., et al. (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism, 73, 18-29. (Pubitemid 21901094)
62. Abraham, J., Bakke, S., Rutt, A., et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer, 94, 2333-2343. (Pubitemid 34457113)
63. Sperone, P., Ferrero, A., Daffara, F., et al. (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer, 17, 445-453.
64. Fassnacht, M., Kreissl, M.C., Weismann, D., et al. (2009) New targets and therapeutic approaches for endocrine malignancies. Pharmacology and Therapeutics, 123, 117-141.
65. Samnotra, V., Vassilopoulou-Sellin, R., &, Fojo, A.T., (2007) A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol, supplement, abstract no 15527.
66. Quinkler, M., Hahner, S., Wortmann, S., et al. (2008) Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. Journal of Clinical Endocrinology and Metabolism, 93, 2057-2062. (Pubitemid 351831515)
67. Gross, D.J., Munter, G., Bitan, M., et al. (2006) The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocrine-Related Cancer, 13, 535-540. (Pubitemid 43886675)
68. van Erp, N.P., Gelderblom, H., &, Guchelaar, H.J., (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews, 35, 692-706.
69. Duckett, D.R., &, Cameron, M.D., (2010) Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opinion on Drug Metabolism & Toxicology, 6, 1175-1193.
70. Venkatakrishnan, K., Greenblatt, D.J., von Moltke, L.L., et al. (1998) Alprazolam is another substrate for human cytochrome P450-3A isoforms. Journal of Clinical Psychopharmacology, 18, 256. (Pubitemid 28266896)
71. Gorski, J.C., Hall, S.D., Jones, D.R., et al. (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643-1653. (Pubitemid 24167278)
72. Feierman, D.E., &, Lasker, J.M., (1996) Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metabolism and Disposition, 24, 932-939. (Pubitemid 26314543)
73. Rodrigues, A.D., Roberts, E.M., Mulford, D.J., et al. (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metabolism and Disposition, 25, 623-630. (Pubitemid 27213105)
74. Baker, A.F., &, Dorr, R.T., (2001) Drug interactions with the taxanes: clinical implications. Cancer Treatment Reviews, 27, 221-233. (Pubitemid 32861409)
75. Decker, R.A., Elson, P., Hogan, T.F., et al. (1991) Eastern Cooperative Oncology Group Study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery, 110, 1006-1013.
76. van Slooten, H., &, van Oosterom, A.T., (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treatment Reports, 67, 377-379. (Pubitemid 13054431)
77. Schlumberger, M., Brugieres, L., Gicquel, C., et al. (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer, 67, 2997-3000.